Potential for Specific Dihydropyridine Calcium Channel Blockers to Have a Positive Impact on Cognitive Function in Humans: a Systematic Review

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2015 Jul 3

PMID 26137206

Citations 10

Authors

Jean Peters

Andrew Booth

Ruth Peters

Affiliations

Soon will be listed here.

Abstract

Background: There is some evidence to suggest a possible association between calcium channel blocker (CCB) use and a lower decline in cognitive function compared with use of other hypertensive treatments. In particular, there is an emerging interest in the potential for specific CCBs, particularly the dihydropyridine CCBs nitrendipine, nicardipine, cilnidipine, lercandipine, nimodipine, azelnidipine and nilvadipine. The aim of this review was to assess the evidence relating to these specific CCBs and incident cognitive decline or dementia in humans.

Methods: A systematic review of the literature was carried out. The databases MEDLINE, Embase and PsychINFO were searched from 1980 to 18 April 2014. All abstracts were reviewed by two independent reviewers.

Results: From 753 unique records, 16 full text articles were examined and three retained. The three articles reported data from two studies. A 12-week double-blind randomized controlled trial of nitrendipine compared with cilazapril and a longer and larger double-blind placebo-controlled trial also of nitrendipine, namely the Systolic Hypertension in Europe trial (SYST-EUR). Nitrendipine was associated with a reduction in incident dementia in the SYST-EUR trial. There was no association seen for cognitive outcomes in the smaller trial.

Conclusion: At present there is limited evidence to suggest that nitrendipine may be associated with reduction in incident dementia. This association comes from a single trial and needs to be replicated. Furthermore, there is no high-quality evidence for any of the other potential candidate CCBs.

Citing Articles

Self-Explainable Graph Neural Network for Alzheimer Disease and Related Dementias Risk Prediction: Algorithm Development and Validation Study.

Hu X, Sun Z, Nian Y, Wang Y, Dang Y, Li F JMIR Aging. 2024; 7:e54748.

PMID: 38976869 PMC: 11263893. DOI: 10.2196/54748.

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.

Thuru X, Magnez R, El-Bouazzati H, Vergoten G, Quesnel B, Bailly C Cancers (Basel). 2022; 14(14).

PMID: 35884428 PMC: 9322126. DOI: 10.3390/cancers14143368.

The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design.

Ling Y, Hao Z, Liang D, Zhang C, Liu Y, Wang Y Drug Des Devel Ther. 2021; 15:4289-4338.

PMID: 34675489 PMC: 8520849. DOI: 10.2147/DDDT.S329547.

Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI.

Morin A, Mouzon B, Ferguson S, Paris D, Browning M, Stewart W Acta Neuropathol Commun. 2020; 8(1):166.

PMID: 33076989 PMC: 7574534. DOI: 10.1186/s40478-020-01045-x.

Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Barus R, Bene J, Deguil J, Gautier S, Bordet R Br J Pharmacol. 2019; 176(18):3413-3434.

PMID: 30714122 PMC: 6715604. DOI: 10.1111/bph.14607.

References

Shah K, Qureshi S, Johnson M, Parikh N, Schulz P, Kunik M . Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009; 7(5):250-61. DOI: 10.1016/j.amjopharm.2009.11.001. View

Nimmrich V, Eckert A . Calcium channel blockers and dementia. Br J Pharmacol. 2013; 169(6):1203-10. PMC: 3831702. DOI: 10.1111/bph.12240. View

Frishman W . Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis. 2002; 4(6):380-6. DOI: 10.1097/00132580-200211000-00007. View

Khachaturian A, Zandi P, Lyketsos C, Hayden K, Skoog I, Norton M . Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006; 63(5):686-92. DOI: 10.1001/archneur.63.5.noc60013. View

Duron E, Hanon O . Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis. 2010; 20(3):903-14. DOI: 10.3233/JAD-2010-091552. View

Forette F, Seux M, Staessen J, Thijs L, Babarskiene M, Babeanu S . The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162(18):2046-52. DOI: 10.1001/archinte.162.18.2046. View

Peters R, Booth A, Peters J . A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. J Hypertens. 2014; 32(10):1945-57. DOI: 10.1097/HJH.0000000000000273. View

Maxwell C, Hogan D, Ebly E . Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1999; 161(5):501-6. PMC: 1230578. View

Forette F, Seux M, Staessen J, Thijs L, Birkenhager W, Babarskiene M . Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352(9137):1347-51. DOI: 10.1016/s0140-6736(98)03086-4. View

10.

Tooth L, Ware R, Bain C, Purdie D, Dobson A . Quality of reporting of observational longitudinal research. Am J Epidemiol. 2005; 161(3):280-8. DOI: 10.1093/aje/kwi042. View

11.

Denolle T, Sassano P, Allain H, Bentue-Ferrer D, Breton S, Cimarosti I . Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients. Fundam Clin Pharmacol. 2003; 16(6):527-35. DOI: 10.1046/j.1472-8206.2002.00110.x. View

12.

Trompet S, Westendorp R, Kamper A, de Craen A . Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging. 2006; 29(2):306-8. DOI: 10.1016/j.neurobiolaging.2006.10.006. View

13.

Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J . Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36(6):1218-26. DOI: 10.1161/01.STR.0000166048.35740.a9. View

14.

Fournier A, Oprisiu-Fournier R, Serot J, Godefroy O, Achard J, Faure S . Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009; 9(9):1413-31. DOI: 10.1586/ern.09.89. View

15.

Birks J . Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2001; (1):CD000147. DOI: 10.1002/14651858.CD000147. View

16.

Yasar S, Corrada M, Brookmeyer R, Kawas C . Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 2004; 26(2):157-63. DOI: 10.1016/j.neurobiolaging.2004.03.009. View

17.

Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D . Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur J Pharmacol. 2011; 659(2-3):124-9. DOI: 10.1016/j.ejphar.2011.03.048. View

18.

Skinner M, Futterman A, Morrissette D, Thompson L, Hoffman B, Blaschke T . Atenolol compared with nifedipine: effect on cognitive function and mood in elderly hypertensive patients. Ann Intern Med. 1992; 116(8):615-23. DOI: 10.7326/0003-4819-116-8-615. View

19.

Tisaire-Sanchez J, Roma J, Camacho-Azcargorta I, Bueno-Gomez J, Mora-Macia J, Navarro A . Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc Health Risk Manag. 2007; 2(4):491-8. PMC: 1994004. DOI: 10.2147/vhrm.2006.2.4.491. View

20.

Chang-Quan H, Hui W, Chao-Min W, Zheng-Rong W, Jun-Wen G, Yong-Hong L . The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract. 2011; 65(12):1295-305. DOI: 10.1111/j.1742-1241.2011.02810.x. View